Search Results

BioSet™ XCh is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. These products are indicated to be packed into bony voids or gaps of the skeletal system (e.g., the extremities, spine, ilium and/or pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process.

BioSet™ XCh is a combination of bovine bone chips processed with the BioCleanse Tissue Sterilization Process, human demineralized bone matrix, and a carrier derived from DBM from the same donor. BioSet™ XCh is available in volumes from 1 to 32cc.

The provided text does not contain any information about acceptance criteria or a study that proves the device meets specific performance criteria.

This document is a 510(k) summary for a medical device (BioSet™ XCh), which focuses on demonstrating substantial equivalence to a predicate device rather than presenting performance acceptance criteria or results from a dedicated study.

Here's why the requested information cannot be extracted from the provided text:

• Acceptance Criteria/Device Performance: These are typically quantitative metrics (e.g., sensitivity, specificity, accuracy, mechanical strength, biocompatibility test results) that the device must meet. The document only describes the device's components and intended use.
• Study Details: There's no mention of a clinical trial, in-vitro study, or any other type of study designed to evaluate the BioSet™ XCh's performance against specific endpoints.
• Sample Size, Data Provenance, Experts, Adjudication, MRMC, Standalone Performance, Ground Truth, Training Set: All of these relate to the methodology and results of a performance study, which is absent from this 510(k) summary.

Instead, the document focuses on:

• Substantial Equivalence: Stating that "Data demonstrating substantial equivalence of BioSet™ XCh to predicate devices has been submitted."
• Technological Characteristics Comparison: Highlighting that "The DBM and bovine bone chips are processed in the same manner as the predicate BioSet™ XC. BioSet™ XCh is simply a substitution of human DBM-derived carrier for the porcine gelatin carrier in the BioSet™ XC product."
• Safety Aspects: Mentioning "Viral inactivation studies of the manufacturing process demonstrate a significant reduction of a representative panel of viruses." (While this is a study, it's specific to viral inactivation, not overall device performance or acceptance criteria in the context of efficacy or clinical outcomes).

Therefore, I cannot populate the table or answer the specific questions about acceptance criteria and performance studies based on the provided text.

Ask a specific question about this device

BioSet™ XC is indicated only for bony voids or gaps that are not intrinsic to the stability of the bony structure. These products are indicated to be packed into bony voids or gaps of the skeletal system (e.g., the extremities, spine, ilium and/or pelvis). These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. The product provides a bone void filler that resorbs and is replaced with bone during the healing process.

BioSet™ XC is a combination of bovine bone processed with the BioCleanse Tissue Sterilization Process, human demineralized bone matrix, and porcine gelatin. BioSet™ XC is available in volumes from 1 to 32cc.

The provided text is a 510(k) summary for the BioSet™ XC device and an FDA clearance letter. It does not contain information about acceptance criteria, device performance, a study to prove acceptance criteria, sample sizes, expert involvement, adjudication methods, multi-reader multi-case studies, or standalone algorithm performance.

The document describes the device, its intended use, and its technological characteristics, primarily focusing on its composition and how it relates to predicate devices for demonstrating substantial equivalence. The FDA letter confirms the device's clearance based on this substantial equivalence.

Therefore, I cannot fulfill the request for information regarding acceptance criteria and study details based on the provided text.

Ask a specific question about this device